Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its 2024 annual report

21.02.2025

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the investment areas covered by its portfolio and the companies it is invested in.

In 2024, BB Biotech AG shares delivered a total return of -13.5% in CHF and -14.1% in EUR, including the CHF 2.00 dividend paid in March 2024. Our Net Asset Value (NAV) performance showed greater resilience, increasing by 3.0% in CHF and 1.7% in EUR for the year, while declining by 4.6% in USD. For the full year 2024, BB Biotech AG recorded a net profit of CHF 76 mn compared to a net loss of CHF 207 mn in 2023.

As already announced on January 24, 2025, BB Biotech AG will propose a dividend of CHF 1.80 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech AG shares in December 2024. This marks a continuation of the dividend policy of the previous years.

BB Biotech’s annual report 2024 is available under report.bbbiotech.ch/2024/en resp. www.bbbiotech.com